ライフサイエンスコーパス: mannosamine

1 conversion of UDP-GlcNAc into UDP-N-acetyl-D-mannosamine.

2 The (alpha1-->6)-linked N-acetyl-D-mannosamine-1-phosphate meningococcal capsule of serogro

3 which in Nm serogroup A consists of N-acetyl-mannosamine-1-phosphate units linked together by phospho

4 zene in the presence of Rh2(OAc)4, providing mannosamine 2-N,3-O-oxazolidinones.

5 (Glc6P), and a nonnatural activating sugar, mannosamine 6-phosphate (MaN6P), reveal a binding mode s

6 charide standard plots for respective sugars mannosamine-6-phosphate, sialic acid, galactose- and glu

7 g membranes prepared from cells treated with mannosamine, a GPI biosynthesis inhibitor.

8 , without affecting the incorporation of [3H]mannosamine, a precursor of sialic acid residues.

9 Peracetylated N-azidoacetyl-d-mannosamine (Ac4ManNAz) conjugated with neuroactive carr

10 Mannosamine, an inhibitor of GPI biosynthesis, inhibits

11 In previous studies, mannosamine analogues bearing simple N-acyl groups up to

12 ls were grown in the presence of synthetic d-mannosamine analogues that can modify the conformation o

13 PFAA-derivatized mannosamine and galactosamine were successfully transfor

14 onversion of a panel of azide-functionalized mannosamine and glucosamine derivatives into cell-surfac

15 synthesis through condensation of N-acetyl-D-mannosamine and phosphoenolpyruvate.

16 by metabolic conversion of synthetic N-acyl mannosamines and are typically incorporated into cell-su

17 cells were incubated with different N-acyl-d-mannosamines, and modified forms of GM3 expressed on tum

18 ve activities toward d-allose and N-acetyl-d-mannosamine are largely unaffected by the glucokinase-en

19 Per-butanoylated N-acetyl-D-mannosamine (Bu(4)ManNAc), a SCFA-hexosamine cancer drug

20 by exogenously added N-acetylmannosamine or mannosamine but not by the same concentrations of N-acet

21 Recently, we showed that mannosamine can prevent the growth of P. falciparum by i

22 es that utilize acetyl-CoA to decorate the D-mannosamine capsule of N. meningitidis serogroup A.

23 mine 2-epimerase (wecB) and a UDP-N-acetyl-d-mannosamine dehydrogenase (wecC) were identified in the

24 nthesized by the parasite in the presence of mannosamine demonstrates that the effect is because of t

25 ere was a significant azido-labeled N-acetyl-mannosamine-dependent increase in tumor-to-tissue contra

26 osyl donors for the elaboration of various 2-mannosamine frameworks.

27 a, or uridine but not by control metabolites mannosamine, galactose, mannose, succinate, or pyruvate.

28 h any other sugar, including: galactosamine, mannosamine, Glc, GlcNAc, GalNAc, mannose, 2-deoxyglucos

29 Mannosamine has no effect on the development of either r

30 Starting from the commercially available D-mannosamine hydrochloride (5), gram quantities of both 1

31 two readily available starting materials, D-mannosamine hydrochloride and the microbial oxidation pr

32 ne sulfate, galactosamine hydrochloride, and mannosamine hydrochloride-were examined for the linearit

33 In other systems, mannosamine inhibits GPI biosynthesis by interfering wit

34 The data also show that mannosamine inhibits GPI biosynthesis by interfering wit

35 Peracetylated azido-labeled N-acetyl-mannosamine, injected intraperitoneally, was used as the

36 The d-allose and N-acetyl-d-mannosamine kinases of Escherichia coli K-12 are diverge

37 ody fluids showed an elevation in N-acetyl-D-mannosamine levels, and patient-derived fibroblasts had

38 gulatory functions, was examined utilizing D-mannosamine (ManN) as a tool to identify mannosyltransfe

39 The N-acetyl-D-mannosamine (ManNAc) analog Ac5ManNTGc, a non-natural me

40 an aldolase that cleaves NANA into N-acetyl mannosamine (manNAc) and pyruvate.

41 thway in mammalian cells utilizes N-acetyl-D-mannosamine (ManNAc) as a natural metabolic precursor an

42 we fed the sialic acid precursor N-acetyl-D-mannosamine (ManNAc) to NPHS2-Angptl4 transgenic rats it

43 of glucose (Glc), galactose (Gal), N-acetyl mannosamine (ManNAc), and N-acetylglucosamine (GlcNAc).

44 c acid (Neu5Ac) from pyruvate and N-acetyl-D-mannosamine (ManNAc).

45 riers were then conjugated with N-butanoyl-d-mannosamine (ManNBut) with a goal to achieve modulation

46 reference for the same geometry that put the mannosamine moiety of one substituent close to the thiou

47 ays, precursors based on sialic acid and not mannosamine must be used.

48 he anomeric n-pentenyl glycosides of N-Cbz 2-mannosamine oxazolidinones were converted separately to

49 Treatment with mannosamine precursors of sialic acid (to alter NeuAc/Ne

50 on with the sialic acid precursor N-acetyl-D-mannosamine restored IgG sialylation and preserved insul

51 onjugated with triacetylated N-azidoacetyl-d-mannosamine (RR-S-Ac3 ManNAz) was developed to enable tu

52 ells an unnatural monosaccharide, a modified mannosamine that replaced the acetyl group with a levuli

53 ugate vaccine with systemic N-phenylacetyl-d-mannosamine treatment is a promising immunotherapy for f

54 Mannosamine treatment, which down-regulates cell-surface

55 N-Phenylacetyl-d-mannosamine was efficiently incorporated in a time- and

56 utanoyl, and N-phenylacetyl derivatives of d-mannosamine were synthesized, and their efficiency as bi

57 saccharides, glucosamine, galactosamine, and mannosamine, were derivatized with [Co(DAP)2Cl2]Cl, and

58 with K1 >3000 m(-1) for axially substituted mannosamine, whereas a positively charged version binds

59 An unnatural derivative of N-acetyl-mannosamine, which has a ketone group, was converted to